nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—HRH1—atherosclerosis	0.618	1	CbGaD
Loxapine—HTR2A—arteriole—atherosclerosis	0.00358	0.0969	CbGeAlD
Loxapine—HTR7—vein—atherosclerosis	0.00342	0.0927	CbGeAlD
Loxapine—HTR2A—vein—atherosclerosis	0.00213	0.0578	CbGeAlD
Loxapine—Glaucoma—Niacin—atherosclerosis	0.00213	0.0164	CcSEcCtD
Loxapine—Gynaecomastia—Rosuvastatin—atherosclerosis	0.00197	0.0151	CcSEcCtD
Loxapine—Numbness—Pravastatin—atherosclerosis	0.00191	0.0146	CcSEcCtD
Loxapine—Hepatocellular injury—Ezetimibe—atherosclerosis	0.00183	0.0141	CcSEcCtD
Loxapine—Sensory loss—Pravastatin—atherosclerosis	0.00182	0.014	CcSEcCtD
Loxapine—HTR1B—artery—atherosclerosis	0.00181	0.0489	CbGeAlD
Loxapine—HTR1D—artery—atherosclerosis	0.00175	0.0474	CbGeAlD
Loxapine—Hepatocellular injury—Simvastatin—atherosclerosis	0.00175	0.0134	CcSEcCtD
Loxapine—Gynaecomastia—Lovastatin—atherosclerosis	0.00167	0.0128	CcSEcCtD
Loxapine—Muscle twitching—Niacin—atherosclerosis	0.00163	0.0125	CcSEcCtD
Loxapine—Hepatocellular injury—Pravastatin—atherosclerosis	0.00158	0.0121	CcSEcCtD
Loxapine—Gynaecomastia—Simvastatin—atherosclerosis	0.00156	0.012	CcSEcCtD
Loxapine—Photosensitivity—Lovastatin—atherosclerosis	0.00155	0.0119	CcSEcCtD
Loxapine—Photosensitivity—Ezetimibe—atherosclerosis	0.00152	0.0116	CcSEcCtD
Loxapine—Photosensitivity—Simvastatin—atherosclerosis	0.00145	0.0111	CcSEcCtD
Loxapine—HTR2A—hindlimb—atherosclerosis	0.00142	0.0384	CbGeAlD
Loxapine—Gynaecomastia—Pravastatin—atherosclerosis	0.00141	0.0108	CcSEcCtD
Loxapine—HTR1B—blood vessel—atherosclerosis	0.00141	0.0381	CbGeAlD
Loxapine—HTR7—artery—atherosclerosis	0.00139	0.0377	CbGeAlD
Loxapine—HTR1D—blood vessel—atherosclerosis	0.00136	0.0369	CbGeAlD
Loxapine—Photosensitivity—Pravastatin—atherosclerosis	0.00131	0.01	CcSEcCtD
Loxapine—HTR2A—appendage—atherosclerosis	0.00122	0.0329	CbGeAlD
Loxapine—Jaundice—Rosuvastatin—atherosclerosis	0.0012	0.00923	CcSEcCtD
Loxapine—HTR7—endothelium—atherosclerosis	0.00118	0.0319	CbGeAlD
Loxapine—Urinary retention—Niacin—atherosclerosis	0.00111	0.0085	CcSEcCtD
Loxapine—Hepatitis—Rosuvastatin—atherosclerosis	0.00111	0.0085	CcSEcCtD
Loxapine—HTR7—blood vessel—atherosclerosis	0.00109	0.0294	CbGeAlD
Loxapine—Azatadine—HRH1—atherosclerosis	0.00108	0.131	CrCbGaD
Loxapine—Photosensitivity reaction—Lovastatin—atherosclerosis	0.00107	0.00821	CcSEcCtD
Loxapine—Orthostatic hypotension—Niacin—atherosclerosis	0.00106	0.00817	CcSEcCtD
Loxapine—Chlorcyclizine—HRH1—atherosclerosis	0.00106	0.129	CrCbGaD
Loxapine—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.00105	0.00805	CcSEcCtD
Loxapine—Dysphagia—Niacin—atherosclerosis	0.00101	0.00773	CcSEcCtD
Loxapine—Photosensitivity reaction—Simvastatin—atherosclerosis	0.001	0.00768	CcSEcCtD
Loxapine—Jaundice—Ezetimibe—atherosclerosis	0.001	0.00767	CcSEcCtD
Loxapine—Jaundice—Simvastatin—atherosclerosis	0.000953	0.00731	CcSEcCtD
Loxapine—HRH2—cardiovascular system—atherosclerosis	0.000952	0.0258	CbGeAlD
Loxapine—Hepatitis—Lovastatin—atherosclerosis	0.000939	0.0072	CcSEcCtD
Loxapine—Hepatitis—Ezetimibe—atherosclerosis	0.000921	0.00706	CcSEcCtD
Loxapine—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000905	0.00694	CcSEcCtD
Loxapine—Weight increased—Pravastatin—atherosclerosis	0.000902	0.00692	CcSEcCtD
Loxapine—Weight decreased—Pravastatin—atherosclerosis	0.000897	0.00688	CcSEcCtD
Loxapine—Hepatitis—Simvastatin—atherosclerosis	0.000878	0.00674	CcSEcCtD
Loxapine—Jaundice—Niacin—atherosclerosis	0.000875	0.00672	CcSEcCtD
Loxapine—HTR2A—artery—atherosclerosis	0.000869	0.0235	CbGeAlD
Loxapine—Jaundice—Pravastatin—atherosclerosis	0.000862	0.00661	CcSEcCtD
Loxapine—Cough—Rosuvastatin—atherosclerosis	0.000841	0.00645	CcSEcCtD
Loxapine—Angiopathy—Ezetimibe—atherosclerosis	0.000835	0.00641	CcSEcCtD
Loxapine—Asenapine—HRH1—atherosclerosis	0.00083	0.101	CrCbGaD
Loxapine—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00083	0.00637	CcSEcCtD
Loxapine—Alopecia—Lovastatin—atherosclerosis	0.000829	0.00636	CcSEcCtD
Loxapine—Alopecia—Ezetimibe—atherosclerosis	0.000814	0.00624	CcSEcCtD
Loxapine—Hepatitis—Niacin—atherosclerosis	0.000806	0.00618	CcSEcCtD
Loxapine—Hypoaesthesia—Niacin—atherosclerosis	0.000802	0.00615	CcSEcCtD
Loxapine—Dysgeusia—Lovastatin—atherosclerosis	0.0008	0.00614	CcSEcCtD
Loxapine—Hepatitis—Pravastatin—atherosclerosis	0.000794	0.00609	CcSEcCtD
Loxapine—Confusional state—Rosuvastatin—atherosclerosis	0.000793	0.00609	CcSEcCtD
Loxapine—Hypoaesthesia—Pravastatin—atherosclerosis	0.00079	0.00606	CcSEcCtD
Loxapine—Muscle spasms—Lovastatin—atherosclerosis	0.000786	0.00603	CcSEcCtD
Loxapine—Alopecia—Simvastatin—atherosclerosis	0.000776	0.00595	CcSEcCtD
Loxapine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000772	0.00592	CcSEcCtD
Loxapine—Muscle spasms—Ezetimibe—atherosclerosis	0.000771	0.00591	CcSEcCtD
Loxapine—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00077	0.00591	CcSEcCtD
Loxapine—Vision blurred—Lovastatin—atherosclerosis	0.00077	0.00591	CcSEcCtD
Loxapine—Tremor—Lovastatin—atherosclerosis	0.000766	0.00587	CcSEcCtD
Loxapine—Dysgeusia—Simvastatin—atherosclerosis	0.000748	0.00574	CcSEcCtD
Loxapine—Muscle spasms—Simvastatin—atherosclerosis	0.000735	0.00564	CcSEcCtD
Loxapine—HTR2A—endothelium—atherosclerosis	0.000734	0.0199	CbGeAlD
Loxapine—Angiopathy—Niacin—atherosclerosis	0.000731	0.00561	CcSEcCtD
Loxapine—Leukopenia—Lovastatin—atherosclerosis	0.000731	0.00561	CcSEcCtD
Loxapine—Vision blurred—Simvastatin—atherosclerosis	0.00072	0.00553	CcSEcCtD
Loxapine—Tremor—Simvastatin—atherosclerosis	0.000716	0.00549	CcSEcCtD
Loxapine—Alopecia—Niacin—atherosclerosis	0.000712	0.00547	CcSEcCtD
Loxapine—Insomnia—Rosuvastatin—atherosclerosis	0.000712	0.00546	CcSEcCtD
Loxapine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000707	0.00542	CcSEcCtD
Loxapine—Alopecia—Pravastatin—atherosclerosis	0.000701	0.00538	CcSEcCtD
Loxapine—Cough—Ezetimibe—atherosclerosis	0.000699	0.00537	CcSEcCtD
Loxapine—HTR1D—connective tissue—atherosclerosis	0.000698	0.0189	CbGeAlD
Loxapine—Chest pain—Lovastatin—atherosclerosis	0.000696	0.00534	CcSEcCtD
Loxapine—Hypertension—Ezetimibe—atherosclerosis	0.000692	0.00531	CcSEcCtD
Loxapine—Tension—Niacin—atherosclerosis	0.000689	0.00528	CcSEcCtD
Loxapine—Leukopenia—Simvastatin—atherosclerosis	0.000684	0.00525	CcSEcCtD
Loxapine—Chest pain—Ezetimibe—atherosclerosis	0.000682	0.00523	CcSEcCtD
Loxapine—Dry mouth—Lovastatin—atherosclerosis	0.00068	0.00522	CcSEcCtD
Loxapine—ADRB1—connective tissue—atherosclerosis	0.000679	0.0184	CbGeAlD
Loxapine—Tension—Pravastatin—atherosclerosis	0.000678	0.0052	CcSEcCtD
Loxapine—Dysgeusia—Pravastatin—atherosclerosis	0.000677	0.00519	CcSEcCtD
Loxapine—HTR2A—blood vessel—atherosclerosis	0.000677	0.0183	CbGeAlD
Loxapine—Muscle spasms—Niacin—atherosclerosis	0.000675	0.00518	CcSEcCtD
Loxapine—Constipation—Rosuvastatin—atherosclerosis	0.000673	0.00516	CcSEcCtD
Loxapine—Confusional state—Lovastatin—atherosclerosis	0.000672	0.00516	CcSEcCtD
Loxapine—Dry mouth—Ezetimibe—atherosclerosis	0.000667	0.00512	CcSEcCtD
Loxapine—Muscle spasms—Pravastatin—atherosclerosis	0.000664	0.0051	CcSEcCtD
Loxapine—Vision blurred—Niacin—atherosclerosis	0.000661	0.00507	CcSEcCtD
Loxapine—Confusional state—Ezetimibe—atherosclerosis	0.00066	0.00506	CcSEcCtD
Loxapine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000653	0.00501	CcSEcCtD
Loxapine—Vision blurred—Pravastatin—atherosclerosis	0.000651	0.005	CcSEcCtD
Loxapine—Chest pain—Simvastatin—atherosclerosis	0.000651	0.00499	CcSEcCtD
Loxapine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000648	0.00497	CcSEcCtD
Loxapine—Tremor—Pravastatin—atherosclerosis	0.000647	0.00497	CcSEcCtD
Loxapine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000641	0.00492	CcSEcCtD
Loxapine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00064	0.00491	CcSEcCtD
Loxapine—Syncope—Niacin—atherosclerosis	0.000629	0.00483	CcSEcCtD
Loxapine—Confusional state—Simvastatin—atherosclerosis	0.000629	0.00483	CcSEcCtD
Loxapine—Leukopenia—Niacin—atherosclerosis	0.000628	0.00482	CcSEcCtD
Loxapine—HTR1B—cardiovascular system—atherosclerosis	0.000628	0.017	CbGeAlD
Loxapine—CHRM2—cardiovascular system—atherosclerosis	0.000624	0.0169	CbGeAlD
Loxapine—Oedema—Simvastatin—atherosclerosis	0.000624	0.00479	CcSEcCtD
Loxapine—Leukopenia—Pravastatin—atherosclerosis	0.000619	0.00475	CcSEcCtD
Loxapine—Loss of consciousness—Niacin—atherosclerosis	0.000617	0.00473	CcSEcCtD
Loxapine—Cough—Niacin—atherosclerosis	0.000612	0.0047	CcSEcCtD
Loxapine—Thrombocytopenia—Simvastatin—atherosclerosis	0.000611	0.00469	CcSEcCtD
Loxapine—Cyclizine—HRH1—atherosclerosis	0.000609	0.0739	CrCbGaD
Loxapine—HTR1D—cardiovascular system—atherosclerosis	0.000608	0.0165	CbGeAlD
Loxapine—Insomnia—Lovastatin—atherosclerosis	0.000603	0.00463	CcSEcCtD
Loxapine—Cough—Pravastatin—atherosclerosis	0.000603	0.00463	CcSEcCtD
Loxapine—Paraesthesia—Lovastatin—atherosclerosis	0.000599	0.00459	CcSEcCtD
Loxapine—Hypertension—Pravastatin—atherosclerosis	0.000597	0.00458	CcSEcCtD
Loxapine—Dyspnoea—Lovastatin—atherosclerosis	0.000595	0.00456	CcSEcCtD
Loxapine—Insomnia—Ezetimibe—atherosclerosis	0.000592	0.00454	CcSEcCtD
Loxapine—ADRB1—cardiovascular system—atherosclerosis	0.00059	0.016	CbGeAlD
Loxapine—HRH2—liver—atherosclerosis	0.000589	0.016	CbGeAlD
Loxapine—Chest pain—Pravastatin—atherosclerosis	0.000588	0.00451	CcSEcCtD
Loxapine—Paraesthesia—Ezetimibe—atherosclerosis	0.000587	0.00451	CcSEcCtD
Loxapine—Dry mouth—Niacin—atherosclerosis	0.000584	0.00448	CcSEcCtD
Loxapine—Dyspnoea—Ezetimibe—atherosclerosis	0.000583	0.00447	CcSEcCtD
Loxapine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00058	0.00445	CcSEcCtD
Loxapine—Fatigue—Lovastatin—atherosclerosis	0.000575	0.00441	CcSEcCtD
Loxapine—Oedema—Niacin—atherosclerosis	0.000573	0.00439	CcSEcCtD
Loxapine—Constipation—Lovastatin—atherosclerosis	0.00057	0.00438	CcSEcCtD
Loxapine—Confusional state—Pravastatin—atherosclerosis	0.000569	0.00436	CcSEcCtD
Loxapine—CHRM1—cardiovascular system—atherosclerosis	0.000568	0.0154	CbGeAlD
Loxapine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000565	0.00433	CcSEcCtD
Loxapine—Asthenia—Rosuvastatin—atherosclerosis	0.000565	0.00433	CcSEcCtD
Loxapine—Insomnia—Simvastatin—atherosclerosis	0.000564	0.00433	CcSEcCtD
Loxapine—Oedema—Pravastatin—atherosclerosis	0.000564	0.00433	CcSEcCtD
Loxapine—Fatigue—Ezetimibe—atherosclerosis	0.000564	0.00433	CcSEcCtD
Loxapine—Shock—Niacin—atherosclerosis	0.000563	0.00432	CcSEcCtD
Loxapine—Paraesthesia—Simvastatin—atherosclerosis	0.00056	0.0043	CcSEcCtD
Loxapine—Constipation—Ezetimibe—atherosclerosis	0.000559	0.00429	CcSEcCtD
Loxapine—Tachycardia—Niacin—atherosclerosis	0.000559	0.00429	CcSEcCtD
Loxapine—Pruritus—Rosuvastatin—atherosclerosis	0.000557	0.00427	CcSEcCtD
Loxapine—HTR7—connective tissue—atherosclerosis	0.000556	0.0151	CbGeAlD
Loxapine—Dyspnoea—Simvastatin—atherosclerosis	0.000556	0.00427	CcSEcCtD
Loxapine—Thrombocytopenia—Pravastatin—atherosclerosis	0.000552	0.00424	CcSEcCtD
Loxapine—Feeling abnormal—Lovastatin—atherosclerosis	0.00055	0.00422	CcSEcCtD
Loxapine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000539	0.00414	CcSEcCtD
Loxapine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000539	0.00413	CcSEcCtD
Loxapine—Fatigue—Simvastatin—atherosclerosis	0.000538	0.00413	CcSEcCtD
Loxapine—Azelastine—HRH1—atherosclerosis	0.000537	0.0652	CrCbGaD
Loxapine—Hypotension—Niacin—atherosclerosis	0.000535	0.00411	CcSEcCtD
Loxapine—Constipation—Simvastatin—atherosclerosis	0.000533	0.00409	CcSEcCtD
Loxapine—ADRB1—adipose tissue—atherosclerosis	0.000521	0.0141	CbGeAlD
Loxapine—Dizziness—Rosuvastatin—atherosclerosis	0.00052	0.00399	CcSEcCtD
Loxapine—Insomnia—Niacin—atherosclerosis	0.000518	0.00397	CcSEcCtD
Loxapine—Paraesthesia—Niacin—atherosclerosis	0.000514	0.00395	CcSEcCtD
Loxapine—Feeling abnormal—Simvastatin—atherosclerosis	0.000514	0.00394	CcSEcCtD
Loxapine—Dyspnoea—Niacin—atherosclerosis	0.000511	0.00392	CcSEcCtD
Loxapine—Insomnia—Pravastatin—atherosclerosis	0.00051	0.00391	CcSEcCtD
Loxapine—Somnolence—Niacin—atherosclerosis	0.000509	0.00391	CcSEcCtD
Loxapine—HTR1A—cardiovascular system—atherosclerosis	0.000507	0.0137	CbGeAlD
Loxapine—Paraesthesia—Pravastatin—atherosclerosis	0.000506	0.00388	CcSEcCtD
Loxapine—Dyspnoea—Pravastatin—atherosclerosis	0.000503	0.00386	CcSEcCtD
Loxapine—Rash—Rosuvastatin—atherosclerosis	0.000496	0.00381	CcSEcCtD
Loxapine—Dermatitis—Rosuvastatin—atherosclerosis	0.000496	0.0038	CcSEcCtD
Loxapine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000494	0.00379	CcSEcCtD
Loxapine—Headache—Rosuvastatin—atherosclerosis	0.000493	0.00378	CcSEcCtD
Loxapine—Hypersensitivity—Lovastatin—atherosclerosis	0.000491	0.00377	CcSEcCtD
Loxapine—Fatigue—Pravastatin—atherosclerosis	0.000486	0.00373	CcSEcCtD
Loxapine—Zuclopenthixol—HRH1—atherosclerosis	0.000485	0.0588	CrCbGaD
Loxapine—HTR7—cardiovascular system—atherosclerosis	0.000484	0.0131	CbGeAlD
Loxapine—Constipation—Pravastatin—atherosclerosis	0.000482	0.0037	CcSEcCtD
Loxapine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000482	0.0037	CcSEcCtD
Loxapine—Asthenia—Lovastatin—atherosclerosis	0.000478	0.00367	CcSEcCtD
Loxapine—Cyproheptadine—HRH1—atherosclerosis	0.000477	0.0578	CrCbGaD
Loxapine—Pruritus—Lovastatin—atherosclerosis	0.000472	0.00362	CcSEcCtD
Loxapine—Asthenia—Ezetimibe—atherosclerosis	0.000469	0.0036	CcSEcCtD
Loxapine—Nausea—Rosuvastatin—atherosclerosis	0.000467	0.00359	CcSEcCtD
Loxapine—ADRA1A—cardiovascular system—atherosclerosis	0.000467	0.0127	CbGeAlD
Loxapine—Feeling abnormal—Pravastatin—atherosclerosis	0.000465	0.00357	CcSEcCtD
Loxapine—Pruritus—Ezetimibe—atherosclerosis	0.000463	0.00355	CcSEcCtD
Loxapine—Olanzapine—HRH1—atherosclerosis	0.000462	0.056	CrCbGaD
Loxapine—Hypersensitivity—Simvastatin—atherosclerosis	0.00046	0.00353	CcSEcCtD
Loxapine—CHRM3—adipose tissue—atherosclerosis	0.000448	0.0122	CbGeAlD
Loxapine—Asthenia—Simvastatin—atherosclerosis	0.000448	0.00343	CcSEcCtD
Loxapine—Trazodone—HRH1—atherosclerosis	0.000446	0.0541	CrCbGaD
Loxapine—Pruritus—Simvastatin—atherosclerosis	0.000441	0.00339	CcSEcCtD
Loxapine—Dizziness—Lovastatin—atherosclerosis	0.000441	0.00338	CcSEcCtD
Loxapine—Dizziness—Ezetimibe—atherosclerosis	0.000433	0.00332	CcSEcCtD
Loxapine—Vomiting—Lovastatin—atherosclerosis	0.000424	0.00325	CcSEcCtD
Loxapine—Hypersensitivity—Niacin—atherosclerosis	0.000422	0.00324	CcSEcCtD
Loxapine—Rash—Lovastatin—atherosclerosis	0.00042	0.00323	CcSEcCtD
Loxapine—Dermatitis—Lovastatin—atherosclerosis	0.00042	0.00322	CcSEcCtD
Loxapine—Thiothixene—HRH1—atherosclerosis	0.000418	0.0507	CrCbGaD
Loxapine—Headache—Lovastatin—atherosclerosis	0.000418	0.00321	CcSEcCtD
Loxapine—Vomiting—Ezetimibe—atherosclerosis	0.000416	0.00319	CcSEcCtD
Loxapine—Hypersensitivity—Pravastatin—atherosclerosis	0.000415	0.00319	CcSEcCtD
Loxapine—HRH1—connective tissue—atherosclerosis	0.000415	0.0113	CbGeAlD
Loxapine—Dizziness—Simvastatin—atherosclerosis	0.000412	0.00316	CcSEcCtD
Loxapine—Rash—Ezetimibe—atherosclerosis	0.000412	0.00316	CcSEcCtD
Loxapine—Dermatitis—Ezetimibe—atherosclerosis	0.000412	0.00316	CcSEcCtD
Loxapine—ADRA1A—adipose tissue—atherosclerosis	0.000412	0.0112	CbGeAlD
Loxapine—Asthenia—Niacin—atherosclerosis	0.000411	0.00315	CcSEcCtD
Loxapine—Headache—Ezetimibe—atherosclerosis	0.00041	0.00314	CcSEcCtD
Loxapine—ADRA2A—connective tissue—atherosclerosis	0.000408	0.0111	CbGeAlD
Loxapine—Pruritus—Niacin—atherosclerosis	0.000405	0.00311	CcSEcCtD
Loxapine—Asthenia—Pravastatin—atherosclerosis	0.000405	0.0031	CcSEcCtD
Loxapine—Prochlorperazine—HRH1—atherosclerosis	0.000399	0.0484	CrCbGaD
Loxapine—Pruritus—Pravastatin—atherosclerosis	0.000399	0.00306	CcSEcCtD
Loxapine—Vomiting—Simvastatin—atherosclerosis	0.000397	0.00304	CcSEcCtD
Loxapine—Nausea—Lovastatin—atherosclerosis	0.000396	0.00304	CcSEcCtD
Loxapine—Rash—Simvastatin—atherosclerosis	0.000393	0.00302	CcSEcCtD
Loxapine—Dermatitis—Simvastatin—atherosclerosis	0.000393	0.00301	CcSEcCtD
Loxapine—ADRA2C—adipose tissue—atherosclerosis	0.000392	0.0106	CbGeAlD
Loxapine—Headache—Simvastatin—atherosclerosis	0.000391	0.003	CcSEcCtD
Loxapine—Nausea—Ezetimibe—atherosclerosis	0.000389	0.00298	CcSEcCtD
Loxapine—Dizziness—Niacin—atherosclerosis	0.000379	0.00291	CcSEcCtD
Loxapine—Dizziness—Pravastatin—atherosclerosis	0.000373	0.00286	CcSEcCtD
Loxapine—Nausea—Simvastatin—atherosclerosis	0.000371	0.00284	CcSEcCtD
Loxapine—Amoxapine—HRH1—atherosclerosis	0.000367	0.0446	CrCbGaD
Loxapine—Vomiting—Niacin—atherosclerosis	0.000364	0.00279	CcSEcCtD
Loxapine—Rash—Niacin—atherosclerosis	0.000361	0.00277	CcSEcCtD
Loxapine—Dermatitis—Niacin—atherosclerosis	0.000361	0.00277	CcSEcCtD
Loxapine—Headache—Niacin—atherosclerosis	0.000359	0.00275	CcSEcCtD
Loxapine—Vomiting—Pravastatin—atherosclerosis	0.000359	0.00275	CcSEcCtD
Loxapine—Rash—Pravastatin—atherosclerosis	0.000356	0.00273	CcSEcCtD
Loxapine—Dermatitis—Pravastatin—atherosclerosis	0.000355	0.00273	CcSEcCtD
Loxapine—Headache—Pravastatin—atherosclerosis	0.000353	0.00271	CcSEcCtD
Loxapine—HTR2A—connective tissue—atherosclerosis	0.000347	0.0094	CbGeAlD
Loxapine—Nausea—Niacin—atherosclerosis	0.00034	0.00261	CcSEcCtD
Loxapine—Nausea—Pravastatin—atherosclerosis	0.000335	0.00257	CcSEcCtD
Loxapine—HRH1—adipose tissue—atherosclerosis	0.000319	0.00864	CbGeAlD
Loxapine—ADRA2A—adipose tissue—atherosclerosis	0.000313	0.00848	CbGeAlD
Loxapine—HTR2A—cardiovascular system—atherosclerosis	0.000302	0.00818	CbGeAlD
Loxapine—HTR7—liver—atherosclerosis	0.000299	0.00811	CbGeAlD
Loxapine—Trifluoperazine—HRH1—atherosclerosis	0.000289	0.035	CrCbGaD
Loxapine—ADRA1A—liver—atherosclerosis	0.000289	0.00783	CbGeAlD
Loxapine—Quetiapine—HRH1—atherosclerosis	0.00028	0.034	CrCbGaD
Loxapine—ADRA2C—liver—atherosclerosis	0.000275	0.00746	CbGeAlD
Loxapine—Clozapine—HRH1—atherosclerosis	0.000241	0.0292	CrCbGaD
Loxapine—HTR2A—liver—atherosclerosis	0.000187	0.00506	CbGeAlD
Loxapine—Olanzapine—ALB—atherosclerosis	0.000107	0.0129	CrCbGaD
Loxapine—Thiothixene—ALB—atherosclerosis	9.65e-05	0.0117	CrCbGaD
Loxapine—Diazepam—ALB—atherosclerosis	5.63e-05	0.00683	CrCbGaD
Loxapine—DRD1—Signaling Pathways—MAPK8—atherosclerosis	3.94e-06	1.91e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	3.94e-06	1.91e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—AKT1—atherosclerosis	3.93e-06	1.91e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	3.93e-06	1.91e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	3.92e-06	1.9e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	3.91e-06	1.9e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—SERPINE1—atherosclerosis	3.9e-06	1.89e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—INS—atherosclerosis	3.89e-06	1.89e-05	CbGpPWpGaD
Loxapine—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	3.89e-06	1.89e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MAPK8—atherosclerosis	3.89e-06	1.89e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	3.89e-06	1.89e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TGFB1—atherosclerosis	3.88e-06	1.88e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—AKT1—atherosclerosis	3.88e-06	1.88e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TGFB1—atherosclerosis	3.88e-06	1.88e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SERPINE1—atherosclerosis	3.86e-06	1.87e-05	CbGpPWpGaD
Loxapine—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	3.86e-06	1.87e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	3.85e-06	1.87e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	3.85e-06	1.87e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	3.85e-06	1.87e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	3.83e-06	1.86e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL6—atherosclerosis	3.83e-06	1.86e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	3.83e-06	1.86e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—MAPK3—atherosclerosis	3.83e-06	1.85e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—VEGFA—atherosclerosis	3.82e-06	1.85e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NOS3—atherosclerosis	3.81e-06	1.85e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL6—atherosclerosis	3.81e-06	1.85e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	3.8e-06	1.84e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL6—atherosclerosis	3.79e-06	1.84e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—STAT3—atherosclerosis	3.78e-06	1.83e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MAPK3—atherosclerosis	3.77e-06	1.83e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	3.77e-06	1.83e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	3.77e-06	1.83e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	3.75e-06	1.82e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NOS3—atherosclerosis	3.75e-06	1.82e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PTGS2—atherosclerosis	3.74e-06	1.81e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NOS3—atherosclerosis	3.73e-06	1.81e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	3.73e-06	1.81e-05	CbGpPWpGaD
Loxapine—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	3.72e-06	1.81e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NOS3—atherosclerosis	3.72e-06	1.8e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TGFB1—atherosclerosis	3.71e-06	1.8e-05	CbGpPWpGaD
Loxapine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	3.7e-06	1.8e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NOS3—atherosclerosis	3.69e-06	1.79e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	3.68e-06	1.78e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	3.67e-06	1.78e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL6—atherosclerosis	3.66e-06	1.78e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TGFB1—atherosclerosis	3.66e-06	1.78e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	3.65e-06	1.77e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MMP9—atherosclerosis	3.64e-06	1.77e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—VEGFA—atherosclerosis	3.64e-06	1.77e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MAPK3—atherosclerosis	3.61e-06	1.75e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	3.61e-06	1.75e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	3.61e-06	1.75e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—STAT3—atherosclerosis	3.6e-06	1.75e-05	CbGpPWpGaD
Loxapine—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	3.6e-06	1.75e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—VEGFA—atherosclerosis	3.59e-06	1.74e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	3.58e-06	1.73e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	3.57e-06	1.73e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—STAT3—atherosclerosis	3.56e-06	1.72e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	3.55e-06	1.72e-05	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	3.55e-06	1.72e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	3.54e-06	1.72e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	3.53e-06	1.71e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—AKT1—atherosclerosis	3.52e-06	1.71e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	3.51e-06	1.7e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TGFB1—atherosclerosis	3.51e-06	1.7e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	3.5e-06	1.7e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—AKT1—atherosclerosis	3.5e-06	1.7e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	3.49e-06	1.69e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MMP9—atherosclerosis	3.49e-06	1.69e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	3.47e-06	1.68e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	3.45e-06	1.67e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MAPK3—atherosclerosis	3.44e-06	1.67e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	3.43e-06	1.66e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	3.41e-06	1.66e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MAPK3—atherosclerosis	3.4e-06	1.65e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	3.39e-06	1.64e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CXCL8—atherosclerosis	3.38e-06	1.64e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	3.38e-06	1.64e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	3.37e-06	1.64e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	3.37e-06	1.64e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	3.36e-06	1.63e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TGFB1—atherosclerosis	3.34e-06	1.62e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	3.34e-06	1.62e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	3.33e-06	1.61e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CXCL8—atherosclerosis	3.32e-06	1.61e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	3.32e-06	1.61e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	3.31e-06	1.61e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CXCL8—atherosclerosis	3.3e-06	1.6e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TGFB1—atherosclerosis	3.3e-06	1.6e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	3.28e-06	1.59e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	3.28e-06	1.59e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	3.27e-06	1.59e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	3.27e-06	1.59e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CXCL8—atherosclerosis	3.27e-06	1.59e-05	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	3.27e-06	1.59e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	3.26e-06	1.58e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	3.24e-06	1.57e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—STAT3—atherosclerosis	3.24e-06	1.57e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	3.23e-06	1.57e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	3.22e-06	1.56e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL6—atherosclerosis	3.22e-06	1.56e-05	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	3.22e-06	1.56e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	3.21e-06	1.56e-05	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	3.21e-06	1.56e-05	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	3.2e-06	1.55e-05	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—AKT1—atherosclerosis	3.19e-06	1.55e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	3.17e-06	1.54e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL6—atherosclerosis	3.16e-06	1.53e-05	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—AKT1—atherosclerosis	3.16e-06	1.53e-05	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	3.15e-06	1.53e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—atherosclerosis	3.15e-06	1.53e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—atherosclerosis	3.14e-06	1.52e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	3.13e-06	1.52e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	3.11e-06	1.51e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—atherosclerosis	3.11e-06	1.51e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	3.1e-06	1.5e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—STAT3—atherosclerosis	3.1e-06	1.5e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	3.1e-06	1.5e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	3.08e-06	1.5e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	3.07e-06	1.49e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MMP9—atherosclerosis	3.06e-06	1.48e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	3.03e-06	1.47e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	3.03e-06	1.47e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—NFKB1—atherosclerosis	3.03e-06	1.47e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	3.01e-06	1.46e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—atherosclerosis	3.01e-06	1.46e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	3e-06	1.46e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	3e-06	1.45e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—atherosclerosis	3e-06	1.45e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—atherosclerosis	2.99e-06	1.45e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	2.98e-06	1.45e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	2.98e-06	1.44e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK8—atherosclerosis	2.98e-06	1.44e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	2.98e-06	1.44e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—NFKB1—atherosclerosis	2.97e-06	1.44e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—atherosclerosis	2.97e-06	1.44e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	2.96e-06	1.44e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.96e-06	1.44e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—atherosclerosis	2.96e-06	1.43e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—NFKB1—atherosclerosis	2.95e-06	1.43e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	2.95e-06	1.43e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	2.95e-06	1.43e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	2.95e-06	1.43e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	2.93e-06	1.42e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	2.93e-06	1.42e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—NFKB1—atherosclerosis	2.93e-06	1.42e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—atherosclerosis	2.92e-06	1.42e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.92e-06	1.42e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—atherosclerosis	2.92e-06	1.42e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	2.92e-06	1.42e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	2.92e-06	1.41e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.91e-06	1.41e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	2.91e-06	1.41e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	2.91e-06	1.41e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK8—atherosclerosis	2.9e-06	1.41e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—atherosclerosis	2.9e-06	1.41e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—atherosclerosis	2.9e-06	1.4e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	2.88e-06	1.4e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK8—atherosclerosis	2.88e-06	1.39e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.87e-06	1.39e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—atherosclerosis	2.87e-06	1.39e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	2.87e-06	1.39e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	2.87e-06	1.39e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	2.86e-06	1.39e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.86e-06	1.39e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—atherosclerosis	2.84e-06	1.38e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	2.82e-06	1.37e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—atherosclerosis	2.8e-06	1.36e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	2.78e-06	1.35e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—atherosclerosis	2.76e-06	1.34e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—atherosclerosis	2.75e-06	1.33e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	2.74e-06	1.33e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	2.74e-06	1.33e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—atherosclerosis	2.72e-06	1.32e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	2.71e-06	1.31e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	2.7e-06	1.31e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—atherosclerosis	2.7e-06	1.31e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—atherosclerosis	2.7e-06	1.31e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—atherosclerosis	2.7e-06	1.31e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	2.69e-06	1.3e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—atherosclerosis	2.68e-06	1.3e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	2.68e-06	1.3e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—atherosclerosis	2.68e-06	1.3e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—atherosclerosis	2.67e-06	1.3e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	2.66e-06	1.29e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—atherosclerosis	2.66e-06	1.29e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	2.66e-06	1.29e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—atherosclerosis	2.66e-06	1.29e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—atherosclerosis	2.65e-06	1.29e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	2.65e-06	1.28e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—atherosclerosis	2.64e-06	1.28e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—atherosclerosis	2.63e-06	1.27e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—atherosclerosis	2.62e-06	1.27e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	2.62e-06	1.27e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK3—atherosclerosis	2.6e-06	1.26e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—atherosclerosis	2.58e-06	1.25e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	2.56e-06	1.24e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK3—atherosclerosis	2.55e-06	1.24e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—atherosclerosis	2.55e-06	1.23e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	2.54e-06	1.23e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK3—atherosclerosis	2.54e-06	1.23e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TGFB1—atherosclerosis	2.52e-06	1.22e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—atherosclerosis	2.52e-06	1.22e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK3—atherosclerosis	2.51e-06	1.22e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	2.5e-06	1.21e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—atherosclerosis	2.48e-06	1.2e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	2.48e-06	1.2e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TGFB1—atherosclerosis	2.48e-06	1.2e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	2.47e-06	1.2e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TGFB1—atherosclerosis	2.46e-06	1.19e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	2.46e-06	1.19e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—atherosclerosis	2.44e-06	1.18e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TGFB1—atherosclerosis	2.44e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	2.44e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	2.43e-06	1.18e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	2.33e-06	1.13e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—atherosclerosis	2.32e-06	1.13e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—atherosclerosis	2.31e-06	1.12e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—atherosclerosis	2.29e-06	1.11e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—atherosclerosis	2.26e-06	1.1e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	2.26e-06	1.1e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—atherosclerosis	2.24e-06	1.09e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—atherosclerosis	2.16e-06	1.05e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—atherosclerosis	2.15e-06	1.04e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—atherosclerosis	2.09e-06	1.02e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—atherosclerosis	2.09e-06	1.01e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	2.07e-06	1e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—atherosclerosis	2.06e-06	1e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—atherosclerosis	2.05e-06	9.92e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—atherosclerosis	2e-06	9.69e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.99e-06	9.64e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	1.93e-06	9.37e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	1.9e-06	9.22e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—atherosclerosis	1.9e-06	9.22e-06	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—atherosclerosis	1.88e-06	9.1e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.87e-06	9.07e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—atherosclerosis	1.87e-06	9.05e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—atherosclerosis	1.86e-06	9.02e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—atherosclerosis	1.85e-06	8.99e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—atherosclerosis	1.84e-06	8.91e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	1.83e-06	8.88e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—atherosclerosis	1.75e-06	8.5e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.73e-06	8.37e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.72e-06	8.35e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—atherosclerosis	1.72e-06	8.32e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—atherosclerosis	1.71e-06	8.3e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	1.7e-06	8.25e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—atherosclerosis	1.69e-06	8.22e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	1.69e-06	8.19e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	1.57e-06	7.61e-06	CbGpPWpGaD
